75504-01-7

Basic information

• Product Name: 2-(1-BroMo-ethyl)-pyridine
• Synonyms: 2-(1-BroMo-ethyl)-pyridine
• CAS NO: 75504-01-7
• Molecular Formula: C₇H₈BrN
• Molecular Weight: 186.04912
• Mol File: 75504-01-7.mol

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 2-(1-BroMo-ethyl)-pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(1-BroMo-ethyl)-pyridine(75504-01-7)
• EPA Substance Registry System: 2-(1-BroMo-ethyl)-pyridine(75504-01-7)

Safety Data

• Hazardous Substances Data: 75504-01-7(Hazardous Substances Data)

Usage

General Description

2-(1-Bromo-ethyl)-pyridine is a chemical compound with the molecular formula C7H8BrN. It is an organic compound that consists of a pyridine ring with a bromoethyl substituent. 2-(1-BroMo-ethyl)-pyridine is commonly used as a building block in the synthesis of pharmaceuticals, agrochemicals, and other organic compounds. It is flammable and should be stored and handled with care. 2-(1-Bromo-ethyl)-pyridine is also used in research and development processes for its unique chemical properties and reactivity. It is important to handle this chemical with appropriate safety precautions and in accordance with relevant regulations and guidelines.

Upstream product

• 100-71-0 2-Ethylpyridine 
• 20988-55-0 1-(pyridine-2-yl)ethanol 
• 1121-60-4 pyridine-2-carbaldehyde 

Downstream Products

• 1619257-75-8 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-3-methyl-2-oxo-1-((S)-1-(pyridin-2-yl)ethyl)piperidin-3-yl)acetic acid 

Relevant articles and documents

Development of 2,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one inhibitors of aldehyde dehydrogenase 1A (ALDH1A) as potential adjuncts to ovarian cancer chemotherapy

There is strong evidence that inhibition of one or more Aldehyde Dehydrogenase 1A (ALDH1A) isoforms may be beneficial in chemotherapy-resistant ovarian cancer and other tumor types. While many previous efforts have focused on development of ALDH1A1 select

Aryl substituted methoxy acetic acid compound and preparation method thereof

The invention discloses an aryl substituted methoxy acetic acid compound and a preparation method thereof. The compound is used for promoting and improving a memory, and the aryl substituted methoxy acetic acid compound comprises a parent nucleus of the structure defined in the description. The preparation method comprises the steps that active pharmaceutical ingredients are subjected to reactions such as catalysis, condensation and the like, heating, stirring, drying and purifying are conducted, and the aryl substituted methoxy acetic acid compound improving and promoting the mouse memory to a certain extent is obtained finally. The aryl substituted methoxy acetic acid compound of which the substituted group is -NHCOPh has a certain effect of promoting the mouse memory, the blank of experimental study of the aryl substituted methoxy acetic acid compound improving and promoting the memory is filled up, and a study basis is provided for further studying and developing synthetic drugs promoting and improving the memory.

SMALL MOLECULE INHIBITORS OF ALDH AND USES THEREOF

This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a thiopyrimidinone structure which function as inhibitors of ALDH protein, and their use as therapeutics for the treatment of cancer and other diseases.

A scalable procedure for light-induced benzylic brominations in continuous flow

A continuous-flow protocol for the bromination of benzylic compounds with N-bromosuccinimide (NBS) is presented. The radical reactions were activated with a readily available household compact fluorescent lamp (CFL) using a simple flow reactor design based on transparent fluorinated ethylene polymer (FEP) tubing. All of the reactions were carried out using acetonitrile as the solvent, thus avoiding hazardous chlorinated solvents such as CCl4. For each substrate, only 1.05 equiv of NBS was necessary to fully transform the benzylic starting material into the corresponding bromide. The general character of the procedure was demonstrated by brominating a diverse set of 19 substrates containing different functional groups. Good to excellent isolated yields were obtained in all cases. The novel flow protocol can be readily scaled to multigram quantities by operating the reactor for longer time periods (throughput 30 mmol h-1), which is not easily possible in batch photochemical reactors. The bromination protocol can also be performed with equal efficiency in a larger flow reactor utilizing a more powerful lamp. For the bromination of phenylacetone as a model, a productivity of 180 mmol h -1 for the desired bromide was achieved.

Discovery of potent and simplified piperidinone-based inhibitors of the MDM2-p53 interaction

Continued optimization of the N-substituent in the piperidinone series provided potent piperidinone-pyridine inhibitors 6, 7, 14, and 15 with improved pharmacokinetic properties in rats. Reducing structure complexity of the N-alkyl substituent led to the discovery of 23, a potent and simplified inhibitor of MDM2. Compound 23 exhibits excellent pharmacokinetic properties and substantial in vivo antitumor activity in the SJSA-1 osteosarcoma xenograft mouse model.

N-alkylation of lactams with secondary heterobenzylic bromides

We herein report a general N-alkylation reaction of lactams with secondary heterobenzylic bromides. This methodology features mild reaction condition, moderate to high product isolation yield, and broad substrate scope. Good chemical and structural tolerance has also been demonstrated by both the secondary heterobenzylic bromides and lactam substrates.

2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS

Provided are compounds of formula I that are useful in the treatment and/or prevention of diseases mediated by deficient levels of glucokinase activity, such as diabetes meilitus. Also provided are methods of treating or preventing diseases and disorders characterized by underactivity of glucokinase or which can be treated by activating glucokinase.

Enantiodiscrimination of racemic electrophiles by diketopiperazine enolates: asymmetric synthesis of methyl 2-amino-3-aryl-butanoates and 3-methyl-aspartates

Enolates of (S)-N,N′-bis-(p-methoxybenzyl)-3-iso-propylpiperazine-2,5-dione exhibit high levels of enantiodiscrimination in alkylations with (RS)-1-aryl-1-bromoethanes and (RS)-2-bromoesters, affording substituted diketopiperazines containing two new stereogenic centres in high de. Deprotection and hydrolysis of the resultant substituted diketopiperazines provides a route to the asymmetric synthesis of homochiral methyl 2-amino-3-aryl-butanoates and 3-methyl-aspartates in high de and ee.

THIENOPYRIMIDINE COMPOUNDS AND USE THEREOF

The present invention provides a compound represented by the formula: wherein R1 is a C1-4 alkyl; R2 is (1) a 5- to 7-membered nitrogen-containing heterocyclic group which may have a substituent selected from the group consisting of (1') a halogen, (2') a hydroxy group, (3') a C1-4 alkyl and (4') a C1-4 alkoxy, (2) a phenyl which may have a substituent selected from the group consisting of (1') a halogen, (2') a C1-4 alkoxy-C1-4 alkyl, (3') a mono-C1-4 alkyl-carbamoyl-C1-4 alkyl, (4') a C1-4 alkoxy and (5') a mono-C1-4 alkylcarbamoyl-C1-4 alkoxy, or the like; R3 is a C1-4 alkyl; R4 is a C1-4 alkoxy, or the like; n is an integer of 1 to 4; or a salt thereof, as a thienopyrimidine compound having gonadotropin-releasing hormone antagonistic activity.

Mechanistic studies of the ring opening reactions of [1,2,3]triazolo[1,5-a]pyridines

A mechanism with radical intervention is proposed for the opening of the triazole ring in [1,2,3] triazolo[1,5-a]pyridines which results in the production of 2- or 2,6-disubstituted pyridines.